When investing in biotech stocks, look for companies with broad pipelines and the potential to obtain multiple blockbuster approvals shortly. Some of these companies are AZN, Biogen, Gilead Sciences, and CRISPR Therapeutics. As a result, these companies are well-positioned to see significant returns in the coming years.
AZN Biotech is a biopharmaceutical company based in Cambridge, England. It specializes in prescription medicines to treat a variety of diseases. Its focus areas include cardiovascular, oncology, respiratory, and immunology. The company also has contributed to efforts to prevent and cure diseases like influenza and malaria. As a result, its stock has grown by over 20% in the last year alone.
AZN has a strong track record of research and a good reputation in the biotechnology industry. It is an A-rated company with a "B" grade for Value and Quality. It has a solid business model, focusing on discovering, developing, manufacturing, and commercializing prescription medicines. It recently completed its Phase III trial, called DELIVER, which showed that the biotech's FARXIGA(r) reduced the risk of cardiovascular death and heart failure. It also showed that the ejection fraction in the heart was reduced mildly, which means that it is a potentially effective medicine for patients with heart failure.
Biogen is an excellent choice if you want to invest in a stock that will increase in value over the next few years. This American multinational biotech company, with a market cap of $31 billion, has a robust pipeline focusing on neurodegenerative diseases. It recently stopped phase three trials for its Alzheimer's disease drug Aducanumab but reversed plans to reach the market in 2020 and be approved by the FDA the following year.
The company has a long history of research and development and is a leading pharmaceutical company with the most successful pipeline in the industry. Warren Buffett's Berkshire Hathaway recently bought more than $192.4 million in Biogen stock. The company's stock rose more than 10% after the FDA approved Aduhelm. Eventually, this could translate into a $10 billion market for Biogen.
Gilead Sciences is a high-quality biotech company with a moat-worthy portfolio of high-margin drugs. Its current portfolio also includes several promising candidates for cancer treatments. This makes Gilead an attractive stock for investors with a long-term horizon. The company is also trading cheaply compared to its large pharmaceutical peers. Gilead is also well-positioned to expand into emerging cell therapies. This makes investing a great place if you're interested in long-term growth and dividends.
The company's latest drug, Biktarvy, is expected to increase sales by a factor of four. In addition, it is patent-protected until 2023. It is also profitable and has a large cash reserve to make acquisitions. However, to remain a top biotech company, Gilead must continue to keep a sharp edge over its competition.
CRISPR Therapeutics is an excellent choice if you're looking for a biotech stock with solid growth potential. Its pipeline includes CTX110, an allogeneic chimeric antigen receptor T cell targeted at CD19, which has received FDA approval for relapsed or refractory B-cell malignancies. The company also has partnered with ViaCyte to develop VCTX210, a gene-editing therapy for sickle cell disease.
CRISPR Therapeutics is a biotech company taking a revolutionary drug development approach. The company is developing therapies for serious diseases such as cancer, Alzheimer's, Parkinson's, and hemophilia. The company has over four years of cash in the bank. Analysts have given the company a "moderate-buy" rating.
Investing in biotechnology stocks can be difficult, but with proper guidance, it can be profitable. This app helps you choose the right biotech stocks based on your personal finance goals and risk profile. The app creates stock lists based on the NASDAQ Composite and S&P 500, which include stable companies that have been in the market for a long time. It even allows you to customize your list using in-app functionality, filters, and powerful search options.